| Description | This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Complement component 5. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human, Monkey |
| Epitope | The epitope is MG1 domain (20-124). |
| Isotype | IgG1, κ |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | DB; ELISA; WB; FC; Neut |
| Application Notes | The antibody is recommended for detection of C5 by ELISA, WB, FC, Neut assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
Figure 1 Anti-C5 Monoclonal Antibody (V3S-0522-YC931) in WB
Western blot analysis of V3S-0522-YC931 was performed by loading Recombinant Human C5 Protein (His tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC931 (2 μg/mL) and HRP Goat Anti-human IgG (H&L) as a secondary antibody. Chemiluminescent detection was performed.
Lane 1: Reducing Antigen (0.1 μg)
Lane 2: Reducing Antigen (0.3 μg)
Lane 3: Reducing Antigen (0.6 μg)
Figure 1 Anti-C5 Monoclonal Antibody (V3S-0522-YC931) in WB
Figure 2 Anti-C5 Monoclonal Antibody (V3S-0522-YC931) in WB
Western blot analysis of V3S-0522-YC931 was performed by loading Recombinant Human C5 Protein (His tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC931 (2 μg/mL) and HRP Goat Anti-human IgG (H&L) as a secondary antibody. Chemiluminescent detection was performed.
Lane 1: Non-Reducing Antigen (0.1 μg)
Lane 2: Non-Reducing Antigen (0.3 μg)
Lane 3: Non-Reducing Antigen (0.6 μg)
Figure 2 Anti-C5 Monoclonal Antibody (V3S-0522-YC931) in WB
Figure 3 Anti-C5 Monoclonal Antibody (V3S-0522-YC931) in DB
Dot blot analysis of V3S-0522-YC931 was performed by coating with Recombinant Human C5 Protein (His tag). V3S-0522-YC931 (2 μg/mL) were probed and HRP Goat Anti-human IgG (H&L) as a secondary antibody.
Figure 3 Anti-C5 Monoclonal Antibody (V3S-0522-YC931) in DB
